Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
678 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01387763 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms(DALIAH) | completed | Phase 3 | 202 | Thomas Stauffer LarsenOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT01721746 | A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | completed | Phase 3 | 405 | Bristol-Myers SquibbINDUSTRY | 14 |
| Apr 19, 2022 |
| clinicaltrials |
| NCT01702571 | A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment | completed | Phase 3 | 2,185 | Hoffmann-La RocheINDUSTRY | 43 | Apr 4, 2022 | clinicaltrials |
| NCT04167436 | Fit for Surgery. Multimodal Prehabilitation in Colorectal Cancer Patients | unknown | Phase 2 / Phase 3 | 48 | Zealand University HospitalOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT01379989 | INOVATYON STUDY -International, Randomized Study in Patients With Ovarian Cancer(INOVATYON) | completed | Phase 3 | 617 | Mario Negri Institute for Pharmacological ResearchOTHER | 11 | Feb 9, 2022 | clinicaltrials |
| NCT03669588 | An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness(ADAPT) | completed | Phase 3 | 167 | argenxINDUSTRY | 16 | Feb 8, 2022 | clinicaltrials |
| NCT03763422 | Trial in Low Grade Glioma Patients: Wait or Treat(IWOT) | terminated | Phase 3 | 19 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 10 | Feb 1, 2022 | clinicaltrials |
| NCT03085095 | A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer(HERO) | completed | Phase 3 | 1,134 | Myovant Sciences GmbHINDUSTRY | 22 | Jan 18, 2022 | clinicaltrials |
| NCT01712789 | Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma(STRATUS) | completed | Phase 3 | 682 | CelgeneINDUSTRY | 20 | Jan 10, 2022 | clinicaltrials |
| NCT03668639 | Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin | unknown | Phase 2 / Phase 3 | 80 | Christina RuhlmannOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT01777152 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas(ECHELON-2) | completed | Phase 3 | 452 | Seagen Inc.INDUSTRY | 16 | Nov 30, 2021 | clinicaltrials |
| NCT02474355 | Real World Treatment Study of AZD9291 for Advanced/Metastatic EGFR T790M Mutation NSCLC(ASTRIS) | completed | Phase 3 | 3,017 | AstraZenecaINDUSTRY | 16 | Nov 11, 2021 | clinicaltrials |
| NCT01596114 | European Stop Tyrosine Kinase Inhibitor Study(EURO-SKI) | completed | Phase 3 | 868 | European LeukemiaNetNETWORK | 10 | Nov 5, 2021 | clinicaltrials |
| NCT00078832 | Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer(IBIS II) | completed | Phase 3 | 3,864 | Queen Mary University of LondonOTHER | 14 | Oct 6, 2021 | clinicaltrials |
| NCT01077154 | Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) | terminated | Phase 3 | 4,509 | AmgenINDUSTRY | 39 | Sep 28, 2021 | clinicaltrials |
| NCT05046262 | Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study | unknown | Phase 3 | 25 | Bispebjerg HospitalOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT02314117 | A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer(RAINFALL) | completed | Phase 3 | 645 | Eli Lilly and CompanyINDUSTRY | 20 | Aug 26, 2021 | clinicaltrials |
| NCT02737501 | ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants(ALTA-1L) | completed | Phase 3 | 275 | Ariad PharmaceuticalsINDUSTRY | 19 | Aug 20, 2021 | clinicaltrials |
| NCT02165215 | A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors(LAUREL) | completed | Phase 3 | 359 | Hoffmann-La RocheINDUSTRY | 15 | Aug 19, 2021 | clinicaltrials |
| NCT03119857 | Early Rising PSA Endocrine Treatment Versus Chemo-endocrine Therapy- SPCG14 | unknown | Phase 3 | 349 | Göteborg UniversityOTHER | 4 | Aug 18, 2021 | clinicaltrials |
| NCT02100696 | A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors(HICKORY) | completed | Phase 3 | 609 | Hoffmann-La RocheINDUSTRY | 24 | Aug 13, 2021 | clinicaltrials |
| NCT03033511 | A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)(MERU) | terminated | Phase 3 | 748 | AbbVieINDUSTRY | 41 | Jul 29, 2021 | clinicaltrials |
| NCT01743989 | A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML.(ENESTPath) | completed | Phase 3 | 620 | Novartis PharmaceuticalsINDUSTRY | 21 | Jul 15, 2021 | clinicaltrials |
| NCT01964378 | CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to Cancer(CORAL) | terminated | Phase 3 | 200 | Tris Pharma, Inc.INDUSTRY | 14 | Jul 15, 2021 | clinicaltrials |
| NCT02031432 | CORAL XT - Open-label Extension Trial of the CORAL Trial(CORAL XT) | completed | Phase 3 | 76 | Tris Pharma, Inc.INDUSTRY | 10 | Jul 15, 2021 | clinicaltrials |
| NCT03806049 | Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer | withdrawn | Phase 3 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 3 | Jul 15, 2021 | clinicaltrials |
| NCT00878709 | Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer(ExteNET) | completed | Phase 3 | 2,840 | Puma Biotechnology, Inc.INDUSTRY | 40 | Jun 11, 2021 | clinicaltrials |
| NCT01808573 | A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting(NALA) | completed | Phase 3 | 621 | Puma Biotechnology, Inc.INDUSTRY | 28 | Jun 11, 2021 | clinicaltrials |
| NCT03027557 | Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.(DENOCINA) | completed | Phase 3 | 46 | Peter VestergaardOTHER | 1 | May 25, 2021 | clinicaltrials |
| NCT02130557 | A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 3 | 536 | PfizerINDUSTRY | 26 | May 18, 2021 | clinicaltrials |
| NCT02644252 | Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer(Toco-Pulm) | terminated | Phase 3 | 79 | Vejle HospitalOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT01865747 | A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma(METEOR) | completed | Phase 3 | 658 | ExelixisINDUSTRY | 26 | Apr 27, 2021 | clinicaltrials |
| NCT00704730 | Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer(EXAM) | completed | Phase 3 | 330 | ExelixisINDUSTRY | 24 | Apr 20, 2021 | clinicaltrials |
| NCT02661152 | DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.(DAHANCA30) | unknown | Phase 3 | 1,252 | Danish Head and Neck Cancer GroupNETWORK | 1 | Apr 13, 2021 | clinicaltrials |
| NCT01244191 | Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | terminated | Phase 3 | 1,048 | Daiichi SankyoINDUSTRY | 23 | Apr 6, 2021 | clinicaltrials |
| NCT02111577 | Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer(VIABLE) | completed | Phase 3 | 1,182 | SOTIO a.s.INDUSTRY | 22 | Apr 6, 2021 | clinicaltrials |
| NCT00073528 | Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer | completed | Phase 3 | 1,286 | Novartis PharmaceuticalsINDUSTRY | 29 | Feb 24, 2021 | clinicaltrials |
| NCT01597908 | Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma(COMBI-v) | completed | Phase 3 | 704 | Novartis PharmaceuticalsINDUSTRY | 28 | Feb 24, 2021 | clinicaltrials |
| NCT00866697 | Efficacy and Safety of Pazopanib Monotherapy After First Line Chemotherapy in Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 3 | 940 | Novartis PharmaceuticalsINDUSTRY | 17 | Feb 16, 2021 | clinicaltrials |
| NCT00004179 | Combination Chemotherapy With or Without Rituximab in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | completed | Phase 3 | 475 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 18 | Feb 15, 2021 | clinicaltrials |
| NCT01652261 | Very Early FDG-PET/CT-response Adapted Therapy for Advanced Hodgkin Lymphoma (H11)(H11) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04601116 | The MASTER Study (MAmmary Cancer STatin ER Positive Study) | recruiting | Phase 3 | 3,360 | Aarhus University HospitalOTHER | 1 | Jan 14, 2021 | clinicaltrials |
| NCT00262990 | Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer | completed | Phase 3 | 829 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 17, 2020 | clinicaltrials |
| NCT01235962 | A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)(PROTECT) | completed | Phase 3 | 1,538 | Novartis PharmaceuticalsINDUSTRY | 26 | Nov 23, 2020 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 | Nov 18, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials